CyTOF™ XT PRO
The widest immune coverage, at faster speeds. Identify novel disease drivers and design better therapies.
Receive your quote directly from the manufacturer.
Analyzing immune responses at a scale not possible with other methods, the CyTOF XT PRO system facilitates large immunophenotyping initiatives while meeting regulatory needs for GLP labs. This advanced system brings ease and accuracy to large-scale clinical trials by combining proven reproducibility with enhanced throughput capabilities and 21 CFR Part 11 compliance-enabling software.
The CyTOF XT PRO system takes proven mass cytometry to speeds of up to 4x faster, improves walk-away automation, and advances sample barcoding capabilities to standardize and streamline analysis for larger studies. This powerful cytometry platform with proven sensitivity, high dynamic range and the resolution to capture 50-plus targets simultaneously, including cell surface markers, signaling proteins and cytokines, supports biomarker discovery, patient stratification and treatment response monitoring.
XTra Speed
Combines up to 4x enhanced throughput with automated sample handling to expedite insights.
XTra Reproducibility
Demonstrates consistency across sample collection methods and a <9.2 %CV regardless of workflow, enabling researchers to leverage large cohorts, longitudinal sampling, and multi-site collections with ease and accuracy.
XTra Compliance
Ensures secure and audit-ready data management with integrated 21 CFR Part 11 compliance-enabled software to meet relevant requirements for clinical research.
XTra Scale
Advances barcoding capabilities – a powerful method for harmonizing large datasets of more than 100 samples in a single tube, minimizing technical variability and reducing workflow burdens for clinical trials.
For Research Use Only. Not for use in diagnostic procedures
Integrated platforms for immunotherapy research and biomarker analysis
Immunotherapy has transformed cancer treatment but 60-70% of patients still fail to respond to these treatments. The challenge lies in accurately identifying which patients will benefit from these therapies due to inadequate predictive biomarkers. However, the solution to this extends far beyond simply identifying more biomarkers.
Addressing existing challenges requires integrated platforms that maintain analytical depth while providing the standardization, throughput, and regulatory compliance needed for clinical implementation. Standard Biotools has developed advanced immune profiling technologies that simultaneously capture functional states, rare cell populations, and spatial relationships to help identify predictive biomarkers for immunotherapy response.
Download this SelectScience guide to explore how to:
- Reveal hidden biomarkers via functional immune profiling
- Scale discovery to clinical reality
- Capture spatial context and dynamic range
- Integrate transcriptomics and proteomics
Resource details:
- Document type: SelectScience guide
- Page count: 40
- Read time: 60 mins
- Edition: 1st
Simultaneous detection of cell surface phenotype and intracellular functions with superior signal resolution
This application note outlines the limitations in functional marker detection with
spectral flow cytometry that can be addressed using CyTOF technology. Download your free copy to receive a direct comparison of spectral flow cytometry and CyTOF intracellular detection, as well as case studies demonstrating robust CyTOF analysis of the major type 2 cytokine IL-13 and the immunoregulatory cytokine IL-10 in human cells.
How imaging mass cytometry technology uniquely detects low-abundance biomarkers
This technical note outlines why the high dynamic range of IMC technology is critical for protein quantification and enables the assessment of expression level without saturation of signals. It also outlines the significance of detecting low-level marker expression (highlighting PD-1, PD-L1 and CTLA-4); how IMC technology allows for clear analysis of low-abundance markers, and examples of PD-1, PD-L1 and CTLA-4 marker expression analysis using IMC systems.
